Pancreatic ductal adenocarcinoma (PDAC), already among the deadliest epithelial
malignancies, is rising in both incidence and contribution to overall cancer deaths. Decades …

Pancreatic cancer is a genetic disease, and the recurrent genetic alterations characteristic of
pancreatic cancer indicate the cellular processes that are targeted for malignant …

Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal and treatment-refractory
cancer. Molecular stratification in pancreatic cancer remains rudimentary and does not yet …

Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer entity characterized by a
heterogeneous genetic landscape and an immunosuppressive tumor microenvironment …

Objective Intratumor heterogeneity drives cancer progression and therapy resistance.
However, it has yet to be determined whether and how subpopulations of cancer cells …

The adult healthy human pancreas has been poorly studied given the lack of indication to
obtain tissue from the pancreas in the absence of disease and rapid postmortem …

Pancreatic ductal adenocarcinoma (PDAC) is projected to be the second leading cause of
cancer mortality by 2030. Bulk transcriptomic analyses have distinguished 'classical'from …

Pancreatic ductal adenocarcinoma (PDAC) is the most lethal common malignancy, with little
improvement in patient outcomes over the past decades. Recently, subtypes of pancreatic …

Simple Summary Macrophages are a major component of the pancreatic tumor
microenvironment, and their increased abundance is associated with poor patient survival …

Background A significant gap in pancreatic ductal adenocarcinoma (PDAC) patient's care is
the lack of molecular parameters characterizing tumours and allowing a personalized …